Lartruvo fails confirmatory study; Lilly suspending promotion

Eli Lilly and Co. (NYSE:LLY) said it will suspend promotion of Lartruvo olaratumab after it missed the primary endpoints of the Phase III ANNOUNCE study to treat advanced or metastatic soft tissue sarcoma. The

Read the full 343 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE